Flag of the European Union EU Clinical Trials Register Help

Clinical trials for influenza AND (quadrivalent OR QIV) AND vaccin*

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    70 result(s) found for: influenza AND (quadrivalent OR QIV) AND vaccin*. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2021-003170-31 Sponsor Protocol Number: QHD00027 Start Date*: 2021-08-16
    Sponsor Name:Cardiovascular Non-Invasive Imaging Research Laboratory, Department of Cardiology, Herlev and Gentofte Hospital
    Full Title: Feasibility of Randomizing Danish Citizens Aged 65-79 Years to High-Dose Quadrivalent Influenza Vaccine vs. Standard-Dose Quadrivalent Influenza Vaccine in a Pragmatic Registry-Based Setting
    Medical condition: Prevention of influenza infection in adults aged 65-79 years
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000785-21 Sponsor Protocol Number: GQM11 Start Date*: 2014-07-24
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Lot-to-Lot Consistency Study of a Quadrivalent Influenza Vaccine in Adult and Elderly Subjects
    Medical condition: Prevention of influenza infection in adults from 18 years of age
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001044-35 Sponsor Protocol Number: GQM00016 Start Date*: 2019-02-08
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine in Children Aged 6 months to 17 Years
    Medical condition: Prophylaxis of influenza (Northern Hemisphere 2017-2018 season) in children aged 6 months to 17 years
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-001401-25 Sponsor Protocol Number: QHD00012 Start Date*: 2019-09-27
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Relative Effectiveness of a High-Dose Quadrivalent Influenza Vaccine versus a Standard-Dose Quadrivalent Influenza Vaccine in Subjects 65 Years of Age and Older
    Medical condition: Prevention of influenza infection in adults from 65 years of age and older
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004904-74 Sponsor Protocol Number: INFQ3003 Start Date*: 2017-09-07
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: A Phase III, Observer-Blind, Randomized, Non-influenza Vaccine Comparator-Controlled, Parallel-Group, Multi-Country Study in Children Aged 6-35 Months to Assess the Safety and Efficacy of Abbott’s ...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: SK (Completed) DK (Completed) EE (Ongoing) CZ (Completed) LT (Completed) BG (Completed) IT (Completed) SI (Completed) ES (Completed) FR (Not Authorised) HR (Completed) HU (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2019-000655-14 Sponsor Protocol Number: QHD00011 Start Date*: 2019-07-30
    Sponsor Name:Sanofi Pasteur
    Full Title: Immunogenicity and Safety of a High-Dose Quadrivalent Influenza Vaccine Administered by the Intramuscular Route in Subjects 60 Years of Age and Older
    Medical condition: Prevention of influenza infection in adults from 60 years of age and older
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) DE (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-004753-33 Sponsor Protocol Number: CSLCT-QIV-15-03 Start Date*: 2016-12-15
    Sponsor Name:Seqirus GmbH
    Full Title: A Phase 3, Randomized, Multicenter, Observer-blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with a US-li...
    Medical condition: Prophylaxis for influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-004133-25 Sponsor Protocol Number: CSLCT-QIV-13-02 Start Date*: 2016-12-15
    Sponsor Name:Seqirus GmbH
    Full Title: A Phase 3, Randomized, Multicenter, Observer-Blinded, Noninferiority Study to Evaluate the Immunogenicity and Safety of a Seqirus Quadrivalent Inactivated Influenza Virus Vaccine (Seqirus QIV) with...
    Medical condition: Prophylaxis for influenza virus infection
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001231-51 Sponsor Protocol Number: GQM05 Start Date*: 2014-05-20
    Sponsor Name:Sanofi Pasteur
    Full Title: Efficacy and Immunogenicity Study of Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Healthy Children Aged 6 to 35 Months
    Medical condition: Prevention of influenza infection in children aged 6 to 35 months
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004862 10022001 Influenza (epidemic) LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Completed) ES (Completed) GR (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2008-001303-34 Sponsor Protocol Number: 111295 Start Date*: 2008-06-25
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase I/II, randomized, single blind, controlled study in adults aged 18-60 years to evaluate the immunogenicity, safety and reactogenicity of an adjuvanted influenza vaccine candidate (GSK 21151...
    Medical condition: Immunization of healthy adults aged 18 to 60 years against influenza
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-005482-23 Sponsor Protocol Number: INFQ3002 Start Date*: 2016-07-28
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Randomized, Double-Blind and Active-Controlled Study in Children and Adolescents Aged 3–17 Years to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022005 Influenza viral infections HLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FI (Completed) EE (Completed) HU (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2018-005026-39 Sponsor Protocol Number: QHD04 Start Date*: 2019-02-01
    Sponsor Name:Sanofi Pasteur Inc
    Full Title: Safety and Immunogenicity of Different Dosages of High-Dose Quadrivalent Influenza Vaccine in Children 6 months to 17 Years of Age
    Medical condition: Prevention of influenza infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004721-24 Sponsor Protocol Number: QHD00014 Start Date*: 2020-09-07
    Sponsor Name:Sanofi Pasteur Inc.
    Full Title: Efficacy, Immunogenicity, and Safety of High-Dose Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months through 35 Months of Age
    Medical condition: Prevention of influenza infection in children 6 months through 35 months of age
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-000955-10 Sponsor Protocol Number: 201251 Start Date*: 2014-08-13
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase III, double-blind, randomized, multicenter study to assess safety and immunogenicity of GlaxoSmithKline Biologicals’ Quadrivalent Split Virion Influenza Vaccine (GSK2321138A) manufactured w...
    Medical condition: Healthy volunteers (Active immunization of adults and children against influenza)
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004865 10059430 Influenza immunization LLT
    17.1 100000004862 10022002 Influenza A virus infection LLT
    17.1 100000004862 10022003 Influenza B virus infection LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2015-001514-97 Sponsor Protocol Number: 114541 Start Date*: 2015-05-27
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase 3, observer blind, randomized, non-influenza vaccine comparator-controlled, multi-country and multi-centre study of the efficacy of GSK Biologicals’ quadrivalent, inactivated, split virion,...
    Medical condition: Healthy volunteers (Immunization against influenza in male and female subjects 3 to 8 years of age inclusive)
    Disease:
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-005101-79 Sponsor Protocol Number: GQM04 Start Date*: 2012-10-05
    Sponsor Name:Sanofi Pasteur
    Full Title: Safety and Immunogenicity of a Quadrivalent Influenza Vaccine Administered via the Intramuscular Route in Child/Adolescent and Adult Subjects
    Medical condition: Prophylaxis of influenza in subjects from 9-17 years of age (and adults aged 18 to 60 years).
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-001230-34 Sponsor Protocol Number: 116023 Start Date*: 2012-08-21
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A phase III, open-label, multicentre study to evaluate the immunogenicity, safety and reactogenicity of a revaccination dose of the GlaxoSmithKline Biologicals' quadrivalent seasonal influenza cand...
    Medical condition: Healthy volunteers (Immunization against influenza A and B in children aged 18 to 47 months)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10022001 Influenza (epidemic) LLT
    14.1 10021881 - Infections and infestations 10022003 Influenza B virus infection LLT
    14.1 10021881 - Infections and infestations 10022000 Influenza PT
    14.1 10021881 - Infections and infestations 10022002 Influenza A virus infection LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Completed) CZ (Completed) GB (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002218-38 Sponsor Protocol Number: GQM10 Start Date*: 2019-07-04
    Sponsor Name:Sanofi Pasteur SA
    Full Title: Safety of a Quadrivalent Influenza Vaccine (VaxigripTetraTM) in Subjects Aged 6 Months and Older in Vietnam
    Medical condition: Prophylaxis of influenza in healthy volunteers (6 months and older)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2014-001042-24 Sponsor Protocol Number: INFQ3001 Start Date*: 2015-05-27
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Randomized, Double-Blind, Active-Controlled Study in Adults to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority to Trivalent Influen...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10022005 Influenza viral infections HLT
    18.1 10022891 - Investigations 10062297 Immunology test PT
    18.1 10018065 - General disorders and administration site conditions 10065109 Reactogenicity event PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) LT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-021032-34 Sponsor Protocol Number: 113275 Start Date*: 2010-10-11
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase III, double-blind, randomized study to evaluate the immunogenicity and safety of GSK Biologicals’ quadrivalent influenza vaccine compared to GSK Biologicals’ trivalent influenza vaccine ad...
    Medical condition: Immunization of female and male children aged 3 to 17 years against influenza
    Disease: Version SOC Term Classification Code Term Level
    12.1 10022000 Influenza LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) CZ (Completed) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 07 08:45:04 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA